Due to a perfect storm of contributing factors, pancreatic cancer is probably the most notoriously intractable of all cancer types, with a dismal prognosis and a dearth of effective treatment options. The history of drug development for this disease is littered with failures. There is an urgent need for new approaches, particularly since pancreatic cancer is expected to become the second leading cause of cancer-related mortality by 2030.
A better understanding of the barriers to effective treatment of patients with pancreatic cancer is providing new inroads for discovery, and many experimental regimens have entered clinical testing. Read more . . .